Nano-hydroxyapatite: reading the trials

What the material is

Enamel is about 96 percent mineral by weight, and that mineral is a carbonated, calcium deficient hydroxyapatite rather than the pure stoichiometric form. Synthetic hydroxyapatite used in oral care is manufactured in a range of particle sizes and morphologies, with "nano" denoting particles in the nanometer range, typically similar in scale to the crystallites in enamel itself.¹

Two mechanisms are usually proposed. The first is deposition: particles adsorb to the enamel surface and to the acquired pellicle, filling surface defects and providing a mineral reservoir that can be incorporated during remineralization. The second is occlusion: particles physically plug exposed dentinal tubules, which is the basis of hydroxyapatite's use for sensitivity.

These are genuinely different claims requiring different evidence, and conflating them is the most common error in consumer coverage. Tubule occlusion for sensitivity is a comparatively easy effect to demonstrate. Preventing caries is a much harder claim.

What the meta-analyses found

An updated systematic review and meta-analysis of clinical evidence for caries prevention by hydroxyapatite concluded that the available trials support a caries-preventive effect.² A separate systematic review and meta-analysis focused specifically on hydroxyapatite-based fluoride-free toothpastes and their role in preventing and remineralizing initial caries lesions reached broadly supportive conclusions.³

Individual randomized trials add texture. A triple-blind randomized clinical trial examined hydroxyapatite-fluoride toothpastes and caries activity,⁴ and a further randomized trial assessed hydroxyapatite-containing toothpastes against caries-related variables.⁵ An earlier trial in children compared a hydroxyapatite toothpaste with a fluoride toothpaste for caries prevention and remineralization.⁶ A broader systematic review of fluoride-free toothpastes assessed hydroxyapatite alongside other active ingredients and found it the best supported of them.⁷

That is a real and growing body of work, and it is more than most alternative actives can claim. It should not be dismissed.

What non-inferiority does and does not establish

Much of the hydroxyapatite case rests on non-inferiority trials against fluoride, and this design is widely misreported. A non-inferiority trial does not test whether two treatments are the same. It tests whether the new treatment is worse than the comparator by more than a margin chosen in advance by the investigators.

Three consequences follow. The conclusion depends heavily on how wide that margin was set, and a generous margin makes non-inferiority easier to demonstrate. A failure to detect a difference in an underpowered trial can look like non-inferiority when it is really uninformative. And non-inferiority to fluoride is only as meaningful as the fluoride arm's own performance in that particular trial.

Who funded the research

Manufacturer funding is the norm in dentifrice research. We say so on our baking soda and stannous fluoride pages, and it would be selective to raise it here and nowhere else. The hydroxyapatite literature is distinctive for a different reason, and it concerns where in the evidence hierarchy the commercial interest sits.

The usual structure has a separation of function. Manufacturers fund primary trials, and systematic reviews and meta-analyses are then conducted by independent groups who pool, appraise and adjudicate those trials. The review is the corrective. It is the reason a pooled estimate is treated as stronger evidence than any single sponsored study.

In the hydroxyapatite literature that separation is largely absent at the review level. Two senior scientists in the research department of Dr. Kurt Wolff GmbH & Co. KG, the German manufacturer behind a leading hydroxyapatite dentifrice brand, appear as named co-authors on the principal systematic reviews and meta-analyses of hydroxyapatite for caries prevention, including the 2021 review and the 2024 updated review this article relies on.⁹ Company-affiliated reviews of hydroxyapatite formulation and of hydroxyapatite in children's oral care carry the same authorship.¹⁰

A commentary in Evidence-Based Dentistry asked directly whether there is enough evidence to recommend hydroxyapatite toothpaste for preventing caries, and was considerably more cautious than the reviews it examined.⁶ That is the kind of arm's-length appraisal this field is short of, and anyone forming a view should read it alongside the supportive syntheses.

The comparison with fluoride is the instructive one. The fluoride evidence base includes decades of trials funded by governments, national health services and public research bodies with no product to sell, pooled by reviewers with no stake in the outcome. That is why the two literatures do not carry equal weight even where the reported effect sizes look similar. It is a statement about evidentiary independence, not about chemistry, and it is the single most important thing to hold in mind when a tube claims parity with fluoride.

The comparator nobody runs: saliva

A question the hydroxyapatite literature does not confront directly, and which follows from elementary physical chemistry: saliva is already supersaturated with respect to hydroxyapatite. It carries more calcium and phosphate in solution than would be stable in equilibrium with tooth mineral, which means that at neutral pH the thermodynamic gradient already points toward deposition rather than dissolution. Mineral lost from the enamel surface is continuously replaced without any intervention at all. The mechanism is set out in saliva and oral health.

This makes the proposed mechanism of hydroxyapatite dentifrice unusual to evaluate. It proposes to supply the same mineral, in the same mouth, to a fluid that is already saturated with it. Fluoride does something structurally different: it alters the solubility of the mineral being deposited, producing a phase that withstands a lower pH. Adding hydroxyapatite adds more of the ion already present in excess.

Two mechanisms could still make that worthwhile, and both are plausible. Particles adsorbed to enamel and pellicle may act as a physically localized reservoir at the surface, which is not the same as raising bulk salivary concentration. And during an acid episode, when saliva has become undersaturated, an adjacent solid phase may buffer locally. Neither has been isolated in a clinical trial, and the trials that exist compare hydroxyapatite against fluoride or against placebo dentifrice rather than against the salivary baseline itself.

The word means several different things

There is no single standardized material called nano-hydroxyapatite. Products differ in particle size distribution, crystal morphology, degree of carbonate substitution, whether the particles are aggregated, and the concentration used in the formulation. All of these plausibly affect adsorption to enamel and incorporation into remineralizing mineral.

The practical consequence is that a trial result obtained with one manufacturer's material does not automatically transfer to another product carrying the same words on the tube. Meta-analyses that pool across heterogeneous materials are useful for detecting whether an effect exists at all and less useful for predicting what any particular product will do.

Where this leaves the evidence

Reasonably supported: hydroxyapatite adsorbs to enamel and pellicle; it occludes dentinal tubules and has a defensible case in dentin hypersensitivity; multiple recent meta-analyses report caries-preventive effects; it is the best evidenced of the fluoride-free actives studied to date.

Not established: equivalence to fluoride, which non-inferiority trials do not demonstrate; long-term caries outcomes, since most trials are short relative to the timescale on which caries develops; which specific material properties matter; and how much of the reported effect survives independent replication. Several reviews also rely partly on in vitro and in situ models standing in for clinical caries endpoints.

Elemental purity, and why apatite is a special case

How trace heavy metals enter oral care products through mined mineral feedstocks, and what independent 2025 testing found across the category, is covered in heavy metals testing and is not repeated here. What follows is specific to apatite, and we have not seen it raised in consumer coverage of this ingredient.

Hydroxyapatite is used industrially as a sorbent for removing lead from contaminated water and soil. That is an established remediation application, and it works because of the crystal chemistry: Pb²⁺ exchanges rapidly with Ca²⁺ in the apatite lattice, the two ions being similar enough in charge and radius to substitute.¹¹

The exchange does not stop at simple substitution. Lead uptake proceeds through dissolution of the apatite followed by precipitation of hydroxypyromorphite, Pb₁₀(PO₄)₆(OH)₂, described in the literature as a very stable phase, and it is that stability which makes apatite useful for locking lead out of circulation.¹²

Two qualifications, both of which cut against the alarming reading and belong here for that reason. First, the same stability may reduce bioavailability. Lead immobilized in a pyromorphite lattice is, by design, poorly soluble, and the toxicological significance of tightly bound versus free lead in an ingested trace quantity is not settled. A high total figure and a high absorbed dose are not the same claim.

Second, and more importantly, this is not special pleading against a competitor ingredient. Every mined mineral used in oral care carries the same question: our own formulation contains calcium carbonate, which is in exactly the same category. The distinction that matters is not which mineral a brand chose but whether it tests each lot at a low detection limit and publishes the result. Ours is published in full, including the lead we did find.